Krystal J Thomas-White1, Evann E Hilt1, Cynthia Fok2, Meghan M Pearce1, Elizabeth R Mueller3,4, Stephanie Kliethermes5, Kristin Jacobs6, Michael J Zilliox7, Cynthia Brincat3,4, Travis K Price1, Gina Kuffel8, Paul Schreckenberger9, Xiaowu Gai10, Linda Brubaker11,12, Alan J Wolfe13. 1. Departments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 2. Department of Urology, University of Minnesota, Minneapolis, MN, USA. 3. Departments of Obstetrics & Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 4. Departments of Obstetrics and Gynecology and Urology, Division of Female Pelvic Medicine and Reconstructive Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 5. Departments of Medicine and Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 6. Department of Obstetrics & Gynecology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 7. Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 8. Center for Biomedical Informatics, Loyola Genomics Facility, Loyola University Chicago, Maywood, IL, USA. 9. Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 10. Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA. 11. Departments of Obstetrics & Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. lbrubaker@luc.edu. 12. Departments of Obstetrics and Gynecology and Urology, Division of Female Pelvic Medicine and Reconstructive Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. lbrubaker@luc.edu. 13. Departments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. awolfe@luc.edu.
Abstract
INTRODUCTION AND HYPOTHESIS: Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. We hypothesized that microbiome/microbiota characteristics would relate to clinically relevant treatment response to UUI medication per os. METHODS: Adult women initiating medication treatment orally for UUI and a comparator group of unaffected women were recruited in a tertiary care health-care system. All participants provided baseline clinical data and urine samples. Women with UUI were given 5 mg solifenacin, with potential dose escalation to 10 mg for inadequate UUI symptom control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed using 16S ribosomal RNA (rRNA) gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. RESULTS: Diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Nonresponders had a more diverse community that often included bacteria not typically found in responders. CONCLUSIONS: Knowledge of an individual's urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing, and expanded urine culture provide information about bacteria that appear to be related to UUI incontinence status and treatment response in this population of adult women.
INTRODUCTION AND HYPOTHESIS: Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. We hypothesized that microbiome/microbiota characteristics would relate to clinically relevant treatment response to UUI medication per os. METHODS: Adult women initiating medication treatment orally for UUI and a comparator group of unaffected women were recruited in a tertiary care health-care system. All participants provided baseline clinical data and urine samples. Women with UUI were given 5 mg solifenacin, with potential dose escalation to 10 mg for inadequate UUI symptom control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed using 16S ribosomal RNA (rRNA) gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. RESULTS: Diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Nonresponders had a more diverse community that often included bacteria not typically found in responders. CONCLUSIONS: Knowledge of an individual's urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing, and expanded urine culture provide information about bacteria that appear to be related to UUI incontinence status and treatment response in this population of adult women.
Authors: Evann E Hilt; Kathleen McKinley; Meghan M Pearce; Amy B Rosenfeld; Michael J Zilliox; Elizabeth R Mueller; Linda Brubaker; Xiaowu Gai; Alan J Wolfe; Paul C Schreckenberger Journal: J Clin Microbiol Date: 2013-12-26 Impact factor: 5.948
Authors: Derrick E Fouts; Rembert Pieper; Sebastian Szpakowski; Hans Pohl; Susan Knoblach; Moo-Jin Suh; Shih-Ting Huang; Inger Ljungberg; Bruce M Sprague; Sarah K Lucas; Manolito Torralba; Karen E Nelson; Suzanne L Groah Journal: J Transl Med Date: 2012-08-28 Impact factor: 5.531
Authors: Debbie A Lewis; Richard Brown; Jon Williams; Paul White; S Kim Jacobson; Julian R Marchesi; Marcus J Drake Journal: Front Cell Infect Microbiol Date: 2013-08-15 Impact factor: 5.293
Authors: Elizabeth Southworth; Baylie Hochstedler; Travis K Price; Cara Joyce; Alan J Wolfe; Elizabeth R Mueller Journal: Female Pelvic Med Reconstr Surg Date: 2019 Mar/Apr Impact factor: 2.091